Ramdev Released Research Paper On Coronil

New Delhi : Yoga Guru Ramdev, the founder of Patanjali, released the first scientific research paper on the evidence-based medicine for COVID-19 by his organization. Union Health Minister, Dr Harsh Vardhan, and Union Minister Nitin Gadkari were also present at the event.

The medicine for which the data has been released is named Coronil. In June last year, Patanjali claimed that its Ayurvedic medicine can cure coronavirus infection. Following some controversy on the claims, Patanjali’s Coronil Kit was licensed as an ‘immunity booster’.

Swami Ramdev, at the event, said, that people believe that research work can only be conducted in the West. Especially when it comes to Ayurveda, people look at research work with suspicion. He also said that Coronil has benefited lakhs of people during the pandemic.

In June 2020, Patanjali Ayurved had launched ‘Coronil and Swasari’, which the company claimed was the first Ayurvedic cure for COVID-19, the respiratory disease caused by the novel coronavirus or SARS-CoV-2 virus. Launching a kit of three Ayurvedic medicines at Patanjali Yogpeeth in Haridwar, Uttarakhand, Yoga guru Ramdev had said they are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS.

Ramdev had also said that the medicine could provide ‘100 per cent recovery rate within 3-7 days’.

  • Related Posts

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    UP expands food, drug testing capacity across all 18 divisions

    UP expands food, drug testing capacity across all 18 divisions

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi